There are 2789 resources available
887P - Final results and biomarker analysis from a phase I dose-expansion (part II) study of ISU104 (barecetamab; a novel anti-ErbB3) monotherapy or in combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Sung-Bae Kim
Session: ePoster Display
890P - Concordance analysis of PD-L1 CPS in different sample types of head and neck squamous cell cancer
Presenter: Stijn De Keukeleire
Session: ePoster Display
1075P - Regression tree analysis to identify factors associated with relapse-free survival (RFS) in patients with resected stage III BRAF V600E/K–mutant melanoma
Presenter: Caroline Robert
Session: ePoster Display
1076P - Real-world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group study
Presenter: Mehmet Alpaslan Ozgun
Session: ePoster Display
1077P - Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) undergoing systemic therapy: A systematic literature review (SLR) and meta-analysis (MA) of real-world evidence (RWE)
Presenter: Georgina Long
Session: ePoster Display
1078P - Real-world data on patients with melanoma brain metastases and outcome related to locoregional treatment modalities and systemic therapy
Presenter: Sidsel Pedersen
Session: ePoster Display
1080P - HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program
Presenter: Jean Jacques Grob
Session: ePoster Display